Bitcoin groundbreakers share personal stories of how Bitcoin is changing lives for the better. Host Mauricio Di Bartolomeo, co-founder and CSO of Ledn, speaks with leading Bitcoin voices, entrepreneurs, and human rights advocates to hear their unique journey and practical real-world examples of how Bitcoin has made a positive impact in their lives. Brought to you by Ledn, a leading financial services company built for Bitcoin & digital assets. Ledn offers a suite of lending, saving and tradi ...
…
continue reading
Contenido proporcionado por Seeking Alpha. Todo el contenido del podcast, incluidos episodios, gráficos y descripciones de podcast, lo carga y proporciona directamente Seeking Alpha o su socio de plataforma de podcast. Si cree que alguien está utilizando su trabajo protegido por derechos de autor sin su permiso, puede seguir el proceso descrito aquí https://es.player.fm/legal.
Player FM : aplicación de podcast
¡Desconecta con la aplicación Player FM !
¡Desconecta con la aplicación Player FM !
'We're pretty cheap at the moment' - Cybin CEO Doug Drysdale
MP3•Episodio en casa
Manage episode 440716844 series 3473653
Contenido proporcionado por Seeking Alpha. Todo el contenido del podcast, incluidos episodios, gráficos y descripciones de podcast, lo carga y proporciona directamente Seeking Alpha o su socio de plataforma de podcast. Si cree que alguien está utilizando su trabajo protegido por derechos de autor sin su permiso, puede seguir el proceso descrito aquí https://es.player.fm/legal.
Cybin CEO Doug Drysdale talks to Jason Najum about transforming treatment of mental health disorders with psychedelics (0:45). CYB003, Phase 2 results for depression, moving into Phase 3 (3:00). How deuterated psilocin differentiates Cybin from competiton (10:00). IP and patents - critical to ROI (12:45). Esketamine and is JNJ's Spravato blazing a trail for psychedelics? (14:15) FDA challenges and Lykos lessons (21:20). Strong balance sheet will get it through Phase 3 data (25:50) Stock consolidation and attracting new buyers (30:35).
Episode transcripts
Show Notes:
Imran Khan On Psychedelics - More We Don't Know Than We Do
Psychedelic Stocks: Focus On Their Cash
FDA's MDMA Decision A Setback, But Long-Term Outlook For Psychedelic Stocks Unchanged
De-Risking Psychedelics: Compass Pathways, Cybin And Atai
For full access to analyst ratings, stock quant scores and dividend grades, subscribe to Seeking Alpha Premium at seekingalpha.com/subscriptions
…
continue reading
Episode transcripts
Show Notes:
Imran Khan On Psychedelics - More We Don't Know Than We Do
Psychedelic Stocks: Focus On Their Cash
FDA's MDMA Decision A Setback, But Long-Term Outlook For Psychedelic Stocks Unchanged
De-Risking Psychedelics: Compass Pathways, Cybin And Atai
For full access to analyst ratings, stock quant scores and dividend grades, subscribe to Seeking Alpha Premium at seekingalpha.com/subscriptions
213 episodios
MP3•Episodio en casa
Manage episode 440716844 series 3473653
Contenido proporcionado por Seeking Alpha. Todo el contenido del podcast, incluidos episodios, gráficos y descripciones de podcast, lo carga y proporciona directamente Seeking Alpha o su socio de plataforma de podcast. Si cree que alguien está utilizando su trabajo protegido por derechos de autor sin su permiso, puede seguir el proceso descrito aquí https://es.player.fm/legal.
Cybin CEO Doug Drysdale talks to Jason Najum about transforming treatment of mental health disorders with psychedelics (0:45). CYB003, Phase 2 results for depression, moving into Phase 3 (3:00). How deuterated psilocin differentiates Cybin from competiton (10:00). IP and patents - critical to ROI (12:45). Esketamine and is JNJ's Spravato blazing a trail for psychedelics? (14:15) FDA challenges and Lykos lessons (21:20). Strong balance sheet will get it through Phase 3 data (25:50) Stock consolidation and attracting new buyers (30:35).
Episode transcripts
Show Notes:
Imran Khan On Psychedelics - More We Don't Know Than We Do
Psychedelic Stocks: Focus On Their Cash
FDA's MDMA Decision A Setback, But Long-Term Outlook For Psychedelic Stocks Unchanged
De-Risking Psychedelics: Compass Pathways, Cybin And Atai
For full access to analyst ratings, stock quant scores and dividend grades, subscribe to Seeking Alpha Premium at seekingalpha.com/subscriptions
…
continue reading
Episode transcripts
Show Notes:
Imran Khan On Psychedelics - More We Don't Know Than We Do
Psychedelic Stocks: Focus On Their Cash
FDA's MDMA Decision A Setback, But Long-Term Outlook For Psychedelic Stocks Unchanged
De-Risking Psychedelics: Compass Pathways, Cybin And Atai
For full access to analyst ratings, stock quant scores and dividend grades, subscribe to Seeking Alpha Premium at seekingalpha.com/subscriptions
213 episodios
All episodes
×Bienvenido a Player FM!
Player FM está escaneando la web en busca de podcasts de alta calidad para que los disfrutes en este momento. Es la mejor aplicación de podcast y funciona en Android, iPhone y la web. Regístrate para sincronizar suscripciones a través de dispositivos.